Usana Health Sciences chief sales officer sells $106,669 in stock

Mulham David Mulham, the Chief Sales Officer of USANA Health Sciences Inc . (NYSE:USNA), a company with impressive gross profit margins of 81% and a strong balance sheet showing more cash than debt, sold a significant portion of company stock earlier this week. According to a recent SEC filing, Mulham disposed of 3,234 shares on March 10, 2025, at a weighted average price of approximately $32.98 per share. The transaction, which took place within a price range of $32.97 to $33.01, amounted to a total value of $106,669. Following this sale, Mulham retains ownership of 12,775 shares in the company. The stock, which has gained nearly 12% over the past week, currently appears undervalued according to InvestingPro analysis. For deeper insights into insider trading patterns and comprehensive financial analysis, including 8 additional ProTips, explore the full USANA Health Sciences Pro Research Report on InvestingPro.

In other recent news, USANA Health Sciences reported mixed financial results for the fourth quarter of 2024. The company exceeded analyst expectations with an earnings per share (EPS) of $0.64, surpassing the forecast of $0.49, and revenue of $214 million, which was higher than the anticipated $208.84 million. Despite these positive results, USANA’s full-year guidance for fiscal year 2025 fell short of investor expectations, with projected earnings per share ranging from $2.35 to $3.00, below the consensus estimate of $2.87. Revenue projections for FY2025 were also modest, estimated between $920 million and $1 billion, closely aligning with the consensus of $934.5 million.

The company announced a notable 7% decline in net sales year-over-year for FY2024, with net earnings dropping by 34% compared to the previous year. USANA’s recent acquisition of Hiya Health contributed minimally to the Q4 results but is expected to play a more significant role in the upcoming year, with projected revenue growth of 29-42%. The acquisition aims to strengthen USANA’s presence in the children’s health market. Analysts from Sidoti and Company and D.A. Davidson expressed interest in USANA’s promotional strategies and the potential impact of the Hiya acquisition on future earnings.

USANA’s leadership, including CEO Jim Brown and CFO Doug Hekking, highlighted the company’s strategic initiatives for 2025, which include over 20 new product launches and enhancements to their associate incentive program. Despite challenges in key markets like China, the company remains optimistic about its long-term growth strategy. The recent developments have prompted cautious optimism among investors, with an emphasis on the company’s ability to navigate a challenging market environment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.